PUBLISHER: Greystone Research Associates | PRODUCT CODE: 1367868
PUBLISHER: Greystone Research Associates | PRODUCT CODE: 1367868
Chronic Disease Markets for Sustained Release Injectables - Extended Coverage Version
“Chronic Disease Markets for Sustained Release Injectables: Technology, Therapeutics, Markets and Forecasts ” is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.
The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for injectable drug products engineered for controlled release. Provider organization business managers, healthcare administrators and investors will also benefit from this study.
Engineered Injectables that Address Chronic Conditions
Chronic conditions require drug administration over long periods of time, placing a greater emphasis on self-administration. With the shift away from caregiver interaction, drug safety and compliance/adherence become prominent concerns. These concerns, which are not new, are becoming magnified as the number of powerful new drugs reaching the market increases. For healthcare managers and public health officials, one way to address these issues is less frequent dosing. Using formulation technologies designed to modulate the effect of therapeutic substances, drug developers are creating formulations that exhibit extended-release profiles. These chemistries include polymers such as polyethylene glycol-complexed (PEGylated), which are used to product encapsulated and coated versions of new APIs. The goal is to address the requirement for patient-dependent, and therefore compliance-sensitive, drug treatment protocols such as multiple dosing through controlled release formulations that provide the desired therapeutic effect with dosing of once-a-day or less.
Table of Contents
Executive Summary
- Injectable Drug Market Dynamics
- The Trend toward Self-Administration
- Injectable Drug Formulation Technology
- Innovation in Injectable Device Designs
- Therapeutic Demand Drivers
Market Factors
- Patient Compliance and Ease of Use
- Healthcare Regulations
- Managed Care Initiatives
- Competitive Landscape
- Risk Factors
Sustained release Formulation Technologies
- Biodegradable Polymers
- PEG
- PLA/PLGA
- Polyether ester
- BEPO (MedinCell)
- ChroniJect (Oakwood Laboratories/PharmaSophia)
- CriticalMix (Critical Pharmaceuticals)
- Depofoam (Pacira)
- FluidCrystal (Camarus)
- LinkeRx (Alkermes)
- Medisorb (Alkermes)
- Medusa (Recipharm/Avadel)
- Nanocrystals (Alkermes)
- Optisomes (Talon/Spectrum)
- PolyActive (Octoplus)
- Q-Sphera (Midatech Pharma)
- SABER/SAIB (DURECT)
- SynBiosys (Innocore)
- TransCon (Ascendis)
Physical Process Control Methods
- Supercritical Fluid
- SCF for Nanoparticle Formulations
- Formulplex (Supercritical Solutions)
- Ferro
- SCF extraction of emulsions (SFEE)
Sustained release Injectables - Development Factors
- Formulation Factors
- Stability
- Administration Factors
SR Injectables - Product Analysis
- Aripiprazole
- Aripiprazole lauroxil
- Bupivacaine
- Buprenorphine
- Cytarabine
- Cytarabine & Daunorubicin
- Doxorubicin
- Estradiol
- Exenatide
- Fluphenazine decanoate
- Goserelin acetate
- Granisetron
- Interferon(a)
- Interferon(b)
- Irinotecan
- Lanreotide acetate
- Leuprolide
- Leuprolide Depot
- Medroxyprogesterone
- Naltrexone
- Octreotide acetate
- Olanzapine Pamoate
- Paliperidone palmitate
- Pasireotide
- Pegvaliase-pqpz
- Risperidone
- Testosterone
- Triptorelin
- Triamcinolone acetonide
- Vincristine sulfate
Chronic Disease Markets
- Glycemic Control
- AB101 (Rezolute)
- Hormone Deficiency
- human Growth Hormone/Ascendis Pharma
- Addiction
- CAM2038 (Camurus)
- Pain Management
- Posidur/Durect
- Cardiology
- Treprostinil/Ascendis Pharma
- Neurology
- Relday/Risperidone (DURECT/Zogenix)
- Parkinson's Disease
- Oncology
- CAM2032 (Camurus)
Sustained Release Injectables - Selected Sector Analysis
- Addiction
- Glycemic Control
- Infectious Disease
- Hepatitis
- Neurology
- Schizophrenia
- Bipolar Disorder
- Oncology
- Pain Management
- Reproductive Health
- Fertility
- Endometriosis
- Vasomotor Symptoms associated with Menopause
Company Profiles
- Alkermes
- Amylin
- AntriaBio
- Ascendis Pharma
- AstraZeneca
- Aurobundo
- Avadel
- Biomarin
- Camurus
- Critical Pharmaceuticals
- DURECT
- Eli Lilly
- Enzon
- Ipsen
- Janssen
- NanOlogy
- Novartis
- OctoPlus
- Oakwood Laboratories/PharmaSophia
- Pacira
- PhaseBio Pharmaceuticals
- Recipharm AB
- Roche
- Sanofi
- Taiwan Liposome Company
- Xbrane Bipharma
